Knight Therapeutics Inc.
TSX:GUD.TO · Toronto Stock Exchange
+$0.07 today
Vol 0.04M · Avg 0.10M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$5.4M -224.1% | $4.3M +125.7% | -$16.8M +43.7% | -$29.9M -290.7% | $15.7M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $56.6M +6.5% | $53.1M +5.4% | $50.4M -19.5% | $62.6M +30.7% | $47.9M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | -$3.8M -17.5% | -$3.2M +64.5% | -$9.1M +46.7% | -$17.1M -124.3% | -$7.6M | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $8.1M +336.2% | $1.9M -20.1% | $2.3M +23.3% | $1.9M -38.0% | $3.0M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | $1.9M +109.7% | -$19.6M +29.9% | -$28.0M -180.4% | -$10.0M -1693.1% | $627.0K | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$26.5M -157.9% | -$10.3M -284.5% | $5.6M +121.1% | -$26.4M -407.4% | $8.6M | $592.6M | $1.3B | $626.2M |
| Inventory | -$17.8M -201.5% | -$5.9M -946.8% | $698.0K +106.1% | -$11.4M +33.5% | -$17.2M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $42.1M +6562.2% | $632.0K +102.9% | -$21.6M -170.7% | $30.6M +167.1% | $11.5M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | $4.1M +202.1% | -$4.1M +67.9% | -$12.7M -361.3% | -$2.7M -22.9% | -$2.2M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $12.9M +8484.4% | -$154.0K -100.4% | $37.2M +12.8% | $33.0M +319.7% | -$15.0M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | $70.3M +93.8% | $36.3M +0.9% | $35.9M -11.2% | $40.5M -9.3% | $44.6M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$1.9M +93.9% | -$31.5M -216.0% | -$10.0M +61.4% | -$25.8M +88.5% | -$224.2M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | -$110.1M | $0 | $0 | $0 +100.0% | -$220.4M | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$70.4M +56.7% | -$162.6M +51.4% | -$334.2M -80.2% | -$185.5M -188.4% | -$64.3M | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $112.4M -42.7% | $196.1M -43.2% | $345.5M +129.5% | $150.5M -16.6% | $180.5M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $17.6M +224.6% | -$14.1M -174.4% | $19.0M +913.5% | -$2.3M -101.0% | $223.0M | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$84.1M -595.8% | $17.0M -42.2% | $29.3M +146.5% | -$63.1M +40.1% | -$105.3M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $23.2M +228.5% | -$18.1M -0.1% | -$18.0M -157.2% | $31.5M +321.9% | -$14.2M | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $511.0K | $0 | $0 | $0 | $0 | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | -$6.4M +28.4% | -$8.9M +83.4% | -$53.5M -77.9% | -$30.1M +53.3% | -$64.4M | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$4.3M +34.5% | -$6.6M +30.3% | -$9.5M -127.3% | -$4.2M -1507.1% | $297.0K | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $13.0M +138.8% | -$33.5M +58.6% | -$81.0M -4697.2% | $1.8M +102.3% | -$78.3M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | -$2.9M -274.3% | $1.6M -41.4% | $2.8M -57.2% | $6.6M +240.7% | -$4.7M | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | -$3.7M -117.1% | $21.3M +265.2% | -$12.9M +9.6% | -$14.3M +90.1% | -$143.6M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | $68.4M +1322.5% | $4.8M -81.5% | $26.0M +77.2% | $14.7M +108.2% | -$179.6M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Bright Minds Biosciences Inc.
DRUG.CN
$650.96M
Kneat.com, Inc.
TSX:KSI.TO
$618.13M
Verano Holdings Corp.
VRNO.NE
$594.30M
Vitalhub Corp.
TSX:VHI.TO
$453.89M
Cipher Pharmaceuticals Inc.
TSX:CPH.TO
$408.04M
Cresco Labs Inc.
CL.CN
$407.36M
TerrAscend Corp.
TSX:TSND.TO
$284.80M
Canopy Growth Corporation
TSX:WEED.TO
$244.44M
Aurora Cannabis Inc.
TSX:ACB.TO
$234.78M
OrganiGram Holdings Inc.
TSX:OGI.TO
$189.01M
SEC Filings
Recent regulatory filings
No filings found.
Does GUD.TO generate free cash flow?
Knight Therapeutics Inc. (GUD.TO) generated $68.40M of free cash flow in fiscal 2025.
How much operating cash flow does GUD.TO produce?
Operating cash flow was $70.30M, before capital expenditures of $1.91M.
Explore More
Continue the stock analysis
Jump to another research area for this company.